Supply Chain Intelligence

Lineage Cell Therapeutics, Inc. Supply Chain

LCTX supply chain intelligence for Lineage Cell Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

LCTX ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

7Suppliers
8Customers
3Debt Items
20Related Chains

Lineage Cell Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
B-RILEY-SECURITIES-INC B-RILEY-SECURITIES-INC 92% The Company entered into a sales agreement with B. Riley dated March 22, 2024 (the 'Sales Agreement').
ISRAEL-INNOVATION-AUTHORITY ISRAEL-INNOVATION-AUTHORITY 90% We have received grants under the Innovation Law and are required to pay royalties to the IIA from the revenues generated from the sale of product candidates and related services developed, in whole …
WILLIAM-DEMANT-INVEST WILLIAM-DEMANT-INVEST 80% On August 22, 2025, Lineage and WDI entered into a research collaboration agreement (the RCA) to advance the preclinical development of ReSonance (ANP1) for the treatment of hearing loss (the Project…
APLS Apellis Pharmaceuticals, Inc. 72% velopment laboratories and a cGMP manufacturing facility, is designed and equipped to enable simultaneous cGMP processes and to produce a range of cell therapy products for human use in clinical tria…
APLS Apellis Pharmaceuticals, Inc. 72% Reciprocal relationship from APLS graph: Reciprocal relationship from LCTX graph: velopment laboratories and a cGMP manufacturing facility, is designed and equipped to enable simultaneous cGMP proces…
NVO Novo Nordisk A/S 72% Reciprocal relationship from NVO graph: Reciprocal relationship from LCTX graph: velopment laboratories and a cGMP manufacturing facility, is designed and equipped to enable simultaneous cGMP process…
NVO Novo Nordisk A/S 72% velopment laboratories and a cGMP manufacturing facility, is designed and equipped to enable simultaneous cGMP processes and to produce a range of cell therapy products for human use in clinical tria…

Lineage Cell Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
CANCER-RESEARCH-UK CANCER-RESEARCH-UK 90% Lineage and CRT effectuated the option by simultaneously entering into a license agreement (the “CRT License Agreement”).
HADASIT HADASIT 85% The Hadasit License Agreement was amended on December 17, 2021 by a letter agreement pursuant to which CCN is obligated to pay a maximum of 21.5% of any milestone payments Lineage receives under the …
ROCHE-AGREEMENT ROCHE-AGREEMENT 85% The Hadasit License Agreement was amended on December 17, 2021 by a letter agreement pursuant to which CCN is obligated to pay a maximum of 21.5% of any milestone payments Lineage receives under the …
APLS Apellis Pharmaceuticals, Inc. 72% Reciprocal relationship from APLS graph: Reciprocal relationship from LCTX graph: or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts a…
APLS Apellis Pharmaceuticals, Inc. 72% or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, i…
IMDX Insight Molecular Diagnostics Inc. 72% Reciprocal relationship from IMDX graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from IMDX graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from IMDX g…
NVO Novo Nordisk A/S 72% or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, i…
NVO Novo Nordisk A/S 72% Reciprocal relationship from NVO graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from NVO graph: Reciprocal relationship from LCTX graph: or expanding access. In the United St…

Lineage Cell Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
LCTX-DEBT Debt stack $2.4M 90% Market cache reports total debt of $2.4M.
LCTX-DEBT-10644 Warrants outstanding: 39473688 90% xbrl warrant detail from xbrl 2026-03-31.
LCTX-DEBT-10645 Xbrl Convertible 90% xbrl convertible detail from xbrl 2017-12-31.

Lineage Cell Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Lineage Cell Therapeutics, Inc..

Lineage Cell Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
LCTX-OWNER-BROADWOOD-CAPITAL-INC BROADWOOD CAPITAL INC 90% 13F overlay lists BROADWOOD CAPITAL INC as top holder; 132 tracked holders.

Lineage Cell Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
APLS Apellis Pharmaceuticals, Inc. 100.00 1 ['customer', 'supplier']
IMDX Insight Molecular Diagnostics Inc. 100.00 1 ['customer']
NVO Novo Nordisk A/S 100.00 1 ['customer', 'supplier']
DGX Quest Diagnostics Incorporated 50.00 2
GYRE Gyre Therapeutics, Inc. 50.00 2
SDGR Schrödinger, Inc. 50.00 2
ALNY Alnylam Pharmaceuticals, Inc. 50.00 2
BIIB Biogen Inc. 50.00 2
BIO Bio-Rad Laboratories, Inc. 50.00 2
EVAX Evaxion A/S 50.00 2
HIMS Hims & Hers Health, Inc. 50.00 2
IPHA Innate Pharma S.A. 50.00 2
KRRO Korro Bio, Inc. 50.00 2
NONOF Novo Nordisk A/S 50.00 2
MDGL Madrigal Pharmaceuticals, Inc. 50.00 2
SNY Sanofi 50.00 2
ASND Ascendis Pharma A/S 50.00 2
SNYNF Sanofi 50.00 2
PRTA Prothena Corporation plc 50.00 2
RANI Rani Therapeutics Holdings, Inc. 50.00 2
View LCTX supply chain intel →

Explore the full interactive supply chain map for Lineage Cell Therapeutics, Inc..

Open LCTX supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map